Combination Of Dolutegravir And Lamivudine May Be Noninferior To Triple-Drug Combination In People With HIV-1 Who Are ART-Naive, Research Suggests

Infectious Disease Advisor (3/24, Das) reports researchers found in a primary analysis of the GEMINI-1 and GEMINI-2 trials that at 48 weeks, the combination of dolutegravir (DTG) and lamivudine “was shown to be noninferior to the 3-drug regimen of DTG + t...